Plan I-131 activity for benign and malignant thyroid disease using the Marinelli equation or fixed-activity protocols
Defaults: target 150 Gy for Graves; effective T½ ≈ 5 days when not measured. Adjust based on tracer study or clinic protocol.
\( A_{0}\;[\text{MBq}] = \dfrac{D \times m \times 24.67}{T_{1/2,eff} \times \text{RAIU}\;[\%]} \)
D — target absorbed dose (Gy) · m — thyroid mass (g) · T1/2,eff — effective half-life (days) · RAIU — uptake percentage
| Indication | Target dose (Gy) | Notes |
|---|---|---|
| Graves disease | 150–200 | Aim for hypothyroidism (curative); lower doses → higher relapse rate |
| Toxic adenoma / nodule | 300–400 | Suppressed extranodular tissue spared |
| Toxic MNG | 150–200 | Often higher activity due to lower uptake |
| Benign non-toxic goitre | 100–150 | Volume reduction (~40–60 percent at 1 year) |
| Indication | MBq | mCi |
|---|---|---|
| Graves disease | 370–740 | 10–20 |
| Toxic adenoma / MNG | 555–1110 | 15–30 |
| Post-thyroidectomy ablation (low-risk DTC) | 1110–1850 | 30–50 |
| Ablation (intermediate-risk DTC) | 1850–3700 | 50–100 |
| DTC with locoregional / distant metastases | 3700–7400 | 100–200 |
Calculator is for planning only. Pregnancy and breastfeeding are absolute contraindications. Verify activity with calibrator before administration.